Nordic Nanovector Patent Issues in USA

On January 15, 2014 Nordic Nanovector reported that the U.S. Patent and Trademark Office has issued patent no. 8628749 entitled "RADIOIMMUNOCONJUGATES AND USES THEREOF" (Press release Nordic Nanovector, JAN 15, 2014, View Source [SID:1234500625]). The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy technology including the company’s lead product candidate Betalutin. The expiry date for the patent is 2031.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The issuance of this patent supports our investment in Betalutin, which is currently being developed as a treatment for patients with relapsed B-cell Non-Hodgkin lymphoma," said Jan A. Alfheim, Chief Executive Officer.

"We plan to pursue additional patents to expand the global patent protection of our proprietary technology in order to derive maximum commercial value for our shareholders. We will continue to work diligently toward growing our increasing portfolio of patents while developing and commercializing our radioimmunotherapy product candidates"